content_image/165034.jpg
brands and smaller sizes in certain markets. Despite the headwinds, we saw positive momentum in emerging markets, where sales grew by double digits. 

Operational sales decreased in most of our consumer franchises. However, we saw growth in many product lines, including DABAO ®  skin care products, NICORETTE ® , JOHNSON’S ® , AVEENO ®  and LE PETIT MARSEILLAIS ® , where our science-based innovations and expansion into emerging markets continued to drive strong results. We also introduced new product innovations and line extensions to iconic brands, such as JOHNSON’S ® NATURAL ® , LISTERINE ® ZERO ™ , PRECISE ™  from the makers of TYLENOL ® , ZYRTEC ®  Liquid Gels and CYTOMIMIC ™  technology in several new skin care products. 

Our Consumer business continues to distinguish itself with science-based innovations, proprietary technologies and recommendations by health care professionals. More than a billion people around the world count on our consumer products for themselves and their families. 

## OURENDURING STRENGTH 

With the challenges of 2010 , and within the context of our 125 th anniversary in 2011 , we are reminded more than ever of our heritage. Unwavering commitment to the principles embodied in Our Credo and an appreciation for the elements of our operating model are as strong today as at any time in our history. 

We are not perfect; we will make mistakes. And when we do, we hold ourselves accountable to correct them. That accountability is inherent in Our Credo. Its tenets demand a special level of responsibility … first to patients and customers, then to our employees, our communities and our shareholders. Our Credo remains our North Star. 

Another enduring strength is the character of the people of Johnson & Johnson. Despite diverse businesses, we are united by an extraordinary bond—a commitment to caring for one person at a time and touching the world—originating from Our Credo values. It is a quiet sense of purpose focused around the lives we affect, the families and children we touch, and the professionals who support their health. 

Our products, our pipeline and our global presence make us strong as a company. Our people and Our Credo set us apart. 

## OURCOMMITMENT TO WOMEN AND CHILDREN 

As our businesses have diversified and expanded globally, Johnson & Johnson remains true to the foundation of our company: caring for the health and well-being of mothers and children. We have a heritage unlike any other company. Because we are especially privileged to touch mothers at the most intimate moments with their newborn child, we have a bond forged on deep emotional trust—one that builds a special connection with people. It also magnifies our commitment to help ensure that mothers and children, wherever they may live, enjoy good health care. 

Consistent with our legacy, Johnson & Johnson responded 

Unwav ering commitment t o the principles embodied in Our Cr edo and an appreciation f or the elements of our operating model are as str ong today as at an time in our history. 

preventing diseases and reducing stigma and disability in underserved communities. 

## OURCOMMITMENT TO YOU 

I commit to you, our shareholders, that as we enter 2011, Johnson & Johnson is well-positioned for future growth. We will restore quality and confidence in our products. We will continue to introduce differentiated new products that advance important unmet needs in human health and well-being. We will continue building and advancing pipelines that fuel our long-term success. And we’ll continue expanding into new health care categories and emerging markets that offer unprecedented opportunities to touch more people around the world with better care. 

Most important, we will never lose sight of who we are. Our Credo, our operating model and our people are enduring sources of success. We are deeply committed to the people who use our products, to our employees, to the communities in which we live and work, and to you, our loyal shareholders. 

<img src='content_image/165034.jpg'>

March 16, 2011 

with a five-year commitment to the United Nations’ renewed efforts to advance the Millennium Development Goals of reducing mortality in women and children by 2015 . Our commitment aims to help as many as 120  million women each year for the next five years, reaching 50  countries. It includes initiatives such as mobile health information for expectant mothers, safe birth programs and 200  million doses annually of mebendazole, a treatment for intestinal worms in children. 

In addition to this commitment, we support nearly 650  other philanthropic programs in more than 50  countries. While working on saving and improving the lives of women and children, we also focus on building the skills of people who serve community health needs, as well as 

